Home LiteratureArticle Details
PMID: 16150935 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Dysfunctional T regulatory cells in multiple myeloma.

Blood ·Vol. 107 ·No. 1 ·2006-01-01 ·Pages 301-4

Prabhala RH, Neri P, Bae JE, Tassone P, Shammas MA, Allam CK, Daley JF, Chauhan D, Blanchard E, Thatte HS, Anderson KC, Munshi NC

Abstract

Multiple myeloma (MM) is characterized by the production of monoclonal immunoglobulin and is associated with suppressed uninvolved immunoglobulins and dysfunctional T-cell responses. The biologic basis of this dysfunction remains ill defined. Because T regulatory (T(reg)) cells play an important role in suppressing normal immune responses, we evaluated the potential role of T(reg) cells in immune dysfunction in MM. We observed a significant increase in CD4+ CD25+ T cells in patients with monoclonal gammopathy of undetermined significance (MGUS) and in patients with MM compared with healthy donors (25% and 26%, respectively, vs 14%); however, T(reg) cells as measured by FOXP3 expression are significantly decreased in patients with MGUS and MM compared with healthy donors. Moreover, even when they are added in higher proportions, T(reg) cells in patients with MM and MGUS are unable to suppress anti-CD3-mediated T-cell proliferation. This decreased number and function of T(reg) cells in MGUS and in MM may account, at least in part, for the nonspecific increase in CD4+ CD25+ T cells, thereby contributing to dysfunctional T-cell responses.

MeSH Terms
CD4 Lymphocyte Count Case-Control Studies Cell Proliferation Humans Immunity, Cellular Lymphocyte Activation Monoclonal Gammopathy of Undetermined Significance Multiple Myeloma/immunology T-Lymphocytes, Regulatory/immunology,pathology
Authors & Affiliations
12 authors, click to expand affiliations / ORCID
Prabhala Rao H
Veterans Administration Boston Healthcare System, Harvard Medical School, Boston, MA, USA.
Neri Paola
Bae Jooeun E
Tassone Pierfrancesco
Shammas Masood A
Allam Charles K
Daley John F
Chauhan Dharminder
Blanchard Elizabeth
Thatte Hemant S
Anderson Kenneth C
Munshi Nikhil C
References (29)
29 references, click to expand
  1. Natural versus adaptive regulatory T cells.
    Nat Rev Immunol. 2003 Mar;3(3):253-7 PMID: 12658273
  2. Control of regulatory T cell development by the transcription factor Foxp3.
    Science. 2003 Feb 14;299(5609):1057-61 PMID: 12522256
  3. Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers.
    Clin Cancer Res. 2003 Oct 1;9(12):4404-8 PMID: 14555512
  4. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative.
    Eur J Immunol. 2004 Feb;34(2):336-44 PMID: 14768038
  5. Immunomodulatory drug costimulates T cells via the B7-CD28 pathway.
    Blood. 2004 Mar 1;103(5):1787-90 PMID: 14512311
  6. Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma.
    Blood. 2004 Mar 1;103(5):1755-62 PMID: 14604957
  7. Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells.
    J Immunol. 2004 Jul 15;173(2):1444-53 PMID: 15240741
  8. Advances in biology of multiple myeloma: clinical applications.
    Blood. 2004 Aug 1;104(3):607-18 PMID: 15090448
  9. Suppressor T cells in human diseases.
    J Exp Med. 2004 Aug 2;200(3):273-6 PMID: 15280423
  10. Production of transforming growth factor beta by human T lymphocytes and its potential role in the regulation of T cell growth.
    J Exp Med. 1986 May 1;163(5):1037-50 PMID: 2871125
  11. Renal complications of B-cell dyscrasias.
    N Engl J Med. 1991 Jun 27;324(26):1889-90 PMID: 1904135
  12. Detection of hyperreactive T cells in multiple myeloma by multivalent cross-linking of the CD3/TCR complex.
    Blood. 1991 Oct 1;78(7):1770-80 PMID: 1832993
  13. Immunoregulatory mechanisms in multiple myeloma.
    Hematol Oncol Clin North Am. 1997 Feb;11(1):51-69 PMID: 9081204
  14. Cutting edge: TGF-beta signaling is required for the in vivo expansion and immunosuppressive capacity of regulatory CD4+CD25+ T cells.
    J Immunol. 2004 Dec 1;173(11):6526-31 PMID: 15557141
  15. Targeting multiple myeloma cells and their bone marrow microenvironment.
    Ann N Y Acad Sci. 2004 Dec;1028:390-9 PMID: 15650264
  16. The IL-6R alpha chain controls lung CD4+CD25+ Treg development and function during allergic airway inflammation in vivo.
    J Clin Invest. 2005 Feb;115(2):313-25 PMID: 15668741
  17. A well adapted regulatory contrivance: regulatory T cell development and the forkhead family transcription factor Foxp3.
    Nat Immunol. 2005 Apr;6(4):331-7 PMID: 15785758
  18. Mechanisms of suppression by suppressor T cells.
    Nat Immunol. 2005 Apr;6(4):338-44 PMID: 15785759
  19. Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self.
    Nat Immunol. 2005 Apr;6(4):345-52 PMID: 15785760
  20. Natural regulatory T cells in infectious disease.
    Nat Immunol. 2005 Apr;6(4):353-60 PMID: 15785761
  21. Naive CD4+ T cells from lupus-prone Fas-intact MRL mice display TCR-mediated hyperproliferation due to intrinsic threshold defects in activation.
    J Immunol. 2005 Apr 15;174(8):5100-9 PMID: 15814741
  22. Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine.
    Blood. 2005 Sep 15;106(6):2018-25 PMID: 15914560
  23. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists.
    Ann Rheum Dis. 2005 Oct;64(10):1414-20 PMID: 15843454
  24. Regulatory T cells in autoimmmunity*.
    Annu Rev Immunol. 2000;18:423-49 PMID: 10837065
  25. Ex vivo isolation and characterization of CD4(+)CD25(+) T cells with regulatory properties from human blood.
    J Exp Med. 2001 Jun 4;193(11):1303-10 PMID: 11390437
  26. Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-beta1 and interleukin-10.
    Blood. 2001 Nov 15;98(10):2992-8 PMID: 11698282
  27. Prevalence of monoclonal gammopathy in patients with primary hyperparathyroidism: a prospective study.
    Arch Intern Med. 2002 Feb 25;162(4):464-7 PMID: 11863481
  28. Increase of regulatory T cells in the peripheral blood of cancer patients.
    Clin Cancer Res. 2003 Feb;9(2):606-12 PMID: 12576425
  29. Beta 2-microglobulin as a negative regulator of the immune system: high concentrations of the protein inhibit in vitro generation of functional dendritic cells.
    Blood. 2003 May 15;101(10):4005-12 PMID: 12531797
Article Info
Journal
Blood
Abbr.
Blood
ISSN
0006-4971
DOI
10.1182/blood-2005-08-3101
Published
2006-01-01
Epub
2005-00-08
Pages
301-4
Language
English
Region
United States
NLM ID
7603509
PMCID
PMC1895365
Subset
IM
Grants
PHS HHS · P01-78378 · United States
PHS HHS · P50-100707 · United States
PHS HHS · R01-50947 · United States
External Links
PubMed source DOI: 10.1182/blood-2005-08-3101 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2